Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial

被引：0
|
作者：
Kivitz, Alan [1 ]
Sedova, Liliana [2 ,3 ]
Churchill, Melvin [4 ]
Vizcaya, Cynthia [5 ]
Sutariya, Reema [6 ]
Cao, Wenhao [6 ]
Singhal, Atul [7 ]
机构：
[1] Altoona Ctr Clin Res, Duncansville, PA USA
[2] Inst Rheumatol, Prague, Czech Republic
[3] Charles Univ Prague, Clin Rheumatol, Fac Med 1, Prague, Czech Republic
[4] Arthrit Ctr Nebraska, Lincoln, NE USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Southwest Arthrit Res Grp, Mesquite, TX USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2354
引用
收藏
页码：4750 / 4752
页数：3
相关论文
共 50 条
  • [41] Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
    Fleischmann, Roy
    Hayes, Kyle
    Ahn, Sung-Woo
    Wan, George J.
    Panaccio, Mary
    Karlsson, Daniel
    Furst, Daniel E.
    RHEUMATOLOGY AND THERAPY, 2022, 9 (02) : 649 - 661
  • [42] Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
    Roy Fleischmann
    Kyle Hayes
    Sung-Woo Ahn
    George J. Wan
    Mary Panaccio
    Daniel Karlsson
    Daniel E. Furst
    Rheumatology and Therapy, 2022, 9 : 649 - 661
  • [43] Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial
    Mu, Zepeng
    Wang, Wei
    Wang, Jing
    Lv, Wenshan
    Chen, Ying
    Wang, Fang
    Yu, Xiaolong
    Wang, Yangang
    Cheng, Bingfei
    Wang, Zhongchao
    CLINICAL RHEUMATOLOGY, 2019, 38 (12) : 3511 - 3519
  • [44] Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications
    Zhang, Yi
    Zhou, Hu
    Suo, Shanshan
    Zhuang, Junling
    Yang, Linhua
    He, Aili
    Liu, Qingchi
    Du, Xin
    Gao, Sujun
    Li, Yarong
    Li, Yan
    Chen, Yuqing
    Wu, Wen
    Zhu, Huanling
    He, Guangsheng
    Hong, Mei
    Jiang, Qian
    Jiang, Zhongxing
    Jing, Hongmei
    Wang, Jishi
    Xu, Na
    Yue, Lingling
    Zheng, Cuiping
    Zhou, Zeping
    Jin, Chenghao
    Li, Xin
    Liu, Lin
    Xu, Yajing
    Wu, Dengshu
    Zhang, Feng
    Zhang, Jin
    Xiao, Zhijian
    Jin, Jie
    BLOOD, 2024, 144 : 3165 - 3166
  • [45] MYOSITIS AUTOANTIBODIES AS PREDICTORS OF RESPONSE TO IVIG. POST-HOC ANALYSIS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL
    Charles-Schoeman, Christina
    Schessl, Joachim
    Clodi, Elisabeth
    Aggarwal, Rohit
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (02) : 548 - 549
  • [46] SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS: PREDICTORS OF RESPONSE FROM THE DOUBLE-BLIND, RANDOMISED, PHASE 3B MAXIMISE TRIAL
    Coates, Laura C.
    Baraliakos, Xenofon
    Pournara, Effie
    Gossec, Laure
    Marzo-Ortega, Helena
    Mease, Philip J.
    White, Roisin
    O'brien, Eamonn
    Schulz, Barbara
    RHEUMATOLOGY, 2022, 61 : I143 - I143
  • [47] SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS: PREDICTORS OF RESPONSE FROM THE DOUBLE-BLIND, RANDOMISED, PHASE 3B MAXIMISE TRIAL
    Baraliakos, X.
    Pournara, E.
    Gossec, L.
    Marzo-Ortega, H.
    Mease, P. J.
    White, R.
    O'brien, E.
    Schulz, B.
    Coates, L. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 728 - 728
  • [48] CATEGORIZED HEMATOLOGIC RESPONSE TO PEGCETACOPLAN VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST HOC ANALYSIS OF PEGASUS PHASE 3 RANDOMIZED TRIAL DATA
    Risitano, Antonio
    Weitz, Ilene
    De Castro, Carlos
    Kiladjian, Jean-Jacques
    Griffin, Morag
    Nishimori, Hisakazu
    Al-Adhami, Mohammed
    Chen, Crystal
    Baver, Scott
    De Latour, Regis Peffault
    EXPERIMENTAL HEMATOLOGY, 2021, 100 : S99 - S99
  • [49] Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
    Strand, Vibeke
    Kaeley, Gurjit
    Bergman, Martin
    Gladman, Dafna
    Coates, Laura
    Hur, Peter
    Kim, Nina
    Parikh, Bhumik
    Pertel, Patricia
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [50] SECUKINUMAB RETREATMENT SHOWS RAPID RECAPTURE OF TREATMENT RESPONSE: AN ANALYSIS OF A PHASE 3 EXTENSION TRIAL IN PSORIASIS
    Blauvelt, A.
    Reich, K.
    Warren, R.
    Sigurgeirsson, B.
    Langley, R.
    Papavassilis, C.
    Frueh, J.
    Messina, I
    Bhosekar, V
    Oliver, J.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (11) : 1264 - 1265
12345